(secondQuint)Safety and Efficacy Study of the Trifunctional Antibody Ertumaxomab to Treat Patients With Advanced or Metastatic Breast Cancer.

 A multi-centre, phase II study of ertumaxomab in metastatic breast cancer patients who became progressive after hormonal therapy.

 Each eligible patient will receive three ascending doses of ertumaxomab, administered intravenously.

 Ertumaxomab will be administered as a 3-hour constant rate infusion with a dosing interval of 7 days.

 Each patient will participate in this study for up to 7 months (includes the up to 21 days screening period, 14 days treatment period, and up to 180 days/6 months follow-up), with 3-monthly post-study follow-up until the patient becomes progressive.

.

 Safety and Efficacy Study of the Trifunctional Antibody Ertumaxomab to Treat Patients With Advanced or Metastatic Breast Cancer@highlight

The purpose of this study is to determine the safety and efficacy of the investigational trifunctional anti-Her-2/neu x anti-CD3 antibody ertumaxomab as treatment for hormone therapy refractory Her-2/neu 1+ or 2+ expressing advanced or metastatic breast cancer